Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. - Wikidata - wikimedia - TriplyDB

Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

http://www.wikidata.org/entity/Q33291754

about

Early alterations of brain cellular energy homeostasis in Huntington disease models Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Neurodegenerative disease and adult neurogenesis Triheptanoin improves brain energy metabolism in patients with Huntington disease Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants Besides Huntington's disease, does brain-type creatine kinase play a role in other forms of hearing impairment resulting from a common pathological cause?Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.A two years longitudinal study of a transgenic Huntington disease monkey.Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease.Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression Metformin intake associates with better cognitive function in patients with Huntington's disease.BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer Body composition in premanifest Huntington's disease reveals lower bone density compared to controls Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy No evidence of impaired gastric emptying in early Huntington's Disease.Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort.Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease Huntington's Disease and Striatal Signaling.Progressive Impairment of Lactate-based Gluconeogenesis in the Huntington's Disease Mouse Model R6/2 Cystathionine Levels in Patients With Huntington Disease Quantitative 1H NMR. Development and potential of an analytical method: an update Tissue-specific and nutrient regulation of the branched-chain α-keto acid dehydrogenase phosphatase, protein phosphatase 2Cm (PP2Cm).White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease.Measures of growth in children at risk for Huntington disease Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.A Metabolic Study of Huntington's Disease.Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse Metabolic disruption identified in the Huntington's disease transgenic sheep model.Sleep deficits but no metabolic deficits in premanifest Huntington's disease Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington's disease peripheral blood samples A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease.Molecular mechanisms and potential therapeutical targets in Huntington's disease.

P2860

Q23912810-DBEC5C5E-7053-40A1-9D34-1C1BF85FEDC4 Q24562763-5D728BC1-F060-46C7-89BB-CE6F91625E17 Q28307113-3E6F19AF-87D0-4598-BE13-C059EF46A589 Q28388261-21596020-06BC-486A-8694-3FD3EB3CA47A Q30435217-D74369E1-3959-4C2D-9916-8027BE568C4E Q30474238-23943431-8E10-46AD-8A6A-04B569B0BBC7 Q30497024-8B87D9AA-8F4F-4D70-BC07-4FCDDCA4F91E Q30535295-017448C9-639C-4442-95DD-582EBFEC511E Q30577737-20628C69-49CC-4370-AC59-7A10B0C20366 Q30885784-1D335F2C-D461-4F56-986E-0A6B4174441C Q33690991-D7781A4C-117D-4D64-94AB-190422B53BAD Q33755845-85FD3A38-F78E-4857-8EA3-99A98C0AD795 Q33817346-FE6CFA95-FE25-4C47-956A-91A43E6E67A5 Q33817695-5912AD6C-E032-4AE2-8C22-C149D962708F Q33838303-CA243E06-1470-4C49-A26F-CF8EBDCE9DA7 Q33894661-16506378-8197-44C9-870C-99CC318902AE Q34087126-36A64DCC-A0E6-4E47-A597-00FC2891105B Q34409630-FF070C13-5EAB-4C78-B693-8CB837E41893 Q34775357-B0312E00-1C0B-41C9-9A4A-5AC4B38DE8A1 Q34994813-1F522EC1-A329-44BE-821F-C571BD150D83 Q35079574-B974B08C-1B31-4ABD-A21C-4204DA2303EE Q35086831-BDDBAB47-1EC1-4998-9B32-5F68BF53A4A1 Q35286098-BA69B9BB-4240-43A4-8347-B446DD9D8683 Q35660733-D37F6513-F021-4510-8972-CE2AA3039A64 Q35798834-BCAEFDA7-1243-4567-AA7D-DF4DB7CFB2B4 Q36062737-9E8D7401-A423-4B8B-BFAA-EE11CECB0F4D Q36078735-0C992B6A-E188-42D9-8862-42A9E49D4A5D Q36093756-69A4A273-64B0-4D37-A2EC-F575B13F8975 Q36149988-064314CB-D1D2-46AA-ABFD-333BE4B28A71 Q36315067-C976C32E-2D28-4E2F-BE1D-F1B65C315B1E Q36445216-9D25BC02-3683-46F0-A765-FBCEB462A5BF Q36459384-151DBFC0-A068-47D7-BEEF-C31BAB14BBDB Q36569413-CE9FB5A7-916B-4181-9AE5-8E15A9D1ADE4 Q36799911-E3EB3A4E-53AE-4581-B272-05145E7389EF Q36932534-66BE0EBE-F297-4F00-83D3-E8F23F337D3B Q37014362-CB979CFB-1F18-4782-BAA0-440A1D224656 Q37071213-E285F272-05AA-4713-AD7B-FA2ABD96E9EB Q37131903-0F4A6E3A-4C76-4476-ADA9-9768219F962C Q37154448-E561C5BC-EAC6-4735-BE82-BAD78E234844 Q37776087-1C43DEC1-CCC7-4141-BC46-E36F2AF63A08

P2860

Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

http://www.wikidata.org/entity/Q33291754

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Early energy deficit in Huntin ...... le during disease progression.

@ast

Early energy deficit in Huntin ...... le during disease progression.

@en

Early energy deficit in Huntin ...... le during disease progression.

@nl

type

label

Early energy deficit in Huntin ...... le during disease progression.

@ast

Early energy deficit in Huntin ...... le during disease progression.

@en

Early energy deficit in Huntin ...... le during disease progression.

@nl

prefLabel

Early energy deficit in Huntin ...... le during disease progression.

@ast

Early energy deficit in Huntin ...... le during disease progression.

@en

Early energy deficit in Huntin ...... le during disease progression.

@nl

P1433

Q33291754-C637817E-1731-4F37-AE10-204386DD5859

P1476

Q33291754-BC8431C6-8BF5-4554-9B4C-B86B2D37E0F8

P2093

Q33291754-167F20DC-CEEA-41DC-BB51-27DDC1C9E246

Q33291754-2685F40C-B5D6-4412-8097-9F8256948054

Q33291754-2D11810A-77FC-4CF2-9A26-42355404FB35

Q33291754-3CF152F0-8AA4-404E-91AE-B3D2E4B58976

Q33291754-7779C288-650F-4D9A-BCFB-5305B234563B

Q33291754-97E1F97D-8AC2-41D5-A482-48D0E2EAB680

Q33291754-9E1AF61F-6B0E-4B0A-B6E1-B8C9E8D8B208

Q33291754-A1359628-4C34-4F9C-90F8-76A6CB468547

Q33291754-BE377431-875F-476F-A7D5-7FF18EEE1749

Q33291754-D994EDE8-5BAD-403F-B9EA-A649D8189C48

P2860

Q33291754-000110F6-02A2-4C63-ADF2-4D0DDD24F5FD

Q33291754-037BC6F5-CBA3-4EF6-986C-229B74BED03C

Q33291754-0640EAB9-7C7A-4AC0-BB51-BA15BF1232F6

Q33291754-0A2AC513-BA35-4C6C-9797-D16552BFF4A1

Q33291754-139C2865-9AB1-4324-933C-FFF3472F18D8

Q33291754-15967F1A-A511-416E-AA39-EB1D3D1ADEE2

Q33291754-21319310-5023-4357-9ECC-F84A6CC6569F

Q33291754-243D3611-8D1C-4B07-A40B-FAF2F6133C47

Q33291754-24D075AE-8C21-471F-9F45-E9EF69765F00

Q33291754-2C093A5D-B687-4FEF-BB06-501B20C6C07F

P304

Q33291754-583BDFB4-339B-479B-AB0F-C0BA229DFC55

P31

Q33291754-6CB08ED5-BECF-4B4F-9E2F-89C0DD6CF39D

P356

Q33291754-1558F8AC-ABED-45F4-8459-C11D643A396A

P407

Q33291754-BDA6EAFE-D0FD-46C9-BE9B-06BE0FA8BF7F

P433

Q33291754-7EE57B7C-3C72-40DD-92B1-5215313B69A4

P478

Q33291754-F32790A5-CACF-44C3-B9EC-1519BC5A7BDA

P50

Q33291754-91C2CA6E-B944-4396-ABB6-B1D15EF5CC28

P577

Q33291754-57561B5D-55C3-42FF-869A-7D274BFE765F

P5875

Q33291754-0BE257AF-4C2E-489E-8E6D-88DC84C9BC26

P698

Q33291754-674E1983-DF20-4D4A-B5E6-6DA2D35322EF

P921

Q33291754-4D34907E-9BFB-4EB7-B557-8F615C442561

Q33291754-AFB21B42-8E77-4B7E-8040-B86F8516B0B9

P932

Q33291754-7B286928-8160-4919-984A-3A0115B5E1FE

P356

JOURNAL.PONE.0000647

P1433

P1476

Early energy deficit in Huntin ...... le during disease progression.

@en

P2093

Anne Vassault

http://www.w3.org/2001/XMLSchema#string

Christiane Coussieu

http://www.w3.org/2001/XMLSchema#string

Christiane Gervais

http://www.w3.org/2001/XMLSchema#string

Daniel Rabier

http://www.w3.org/2001/XMLSchema#string

Fanny Mochel

http://www.w3.org/2001/XMLSchema#string

François Seguin

http://www.w3.org/2001/XMLSchema#string

Guislaine Carcelain

http://www.w3.org/2001/XMLSchema#string

Josué Feingold

http://www.w3.org/2001/XMLSchema#string

Julie Barritault

http://www.w3.org/2001/XMLSchema#string

Laurence Perin

http://www.w3.org/2001/XMLSchema#string

P2860

Distribution of key enzymes of branched-chain amino acid metabolism in glial and neuronal cells in culture

Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment

Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease

Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

Metabolic control through the PGC-1 family of transcription coactivators

Recent developments in the investigation of inherited metabolic disorders using cultured human cells.

The energetics of Huntington's disease.

Nutritional regulation of the insulin-like growth factors.

Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR.

P304

e647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0000647

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6186047

http://www.w3.org/2001/XMLSchema#string

P698

17653274

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

1919424

http://www.w3.org/2001/XMLSchema#string